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Background: As Asians are more vulnerable to febrile neutropenia (FN) than Caucasians, evaluations of
FN incidence and risk factors in Asians are important for the appropriate use of primary pegfilgrastim
(PEG-G).
Patients and methods: Japanese breast cancer patients receiving standard adjuvant chemotherapies were
prospectively enrolled in multicenter institutions from August 2015 to July 2017. FN was evaluated from 2
treatment policies: true FN (T-FN): 37.5 C, grade 4 neutropenia, mandatory hospital visit (visiting);
surrogate FN (S-FN): 37.5 C, oral antibiotic, no mandatory visit (non-visiting). PEG-G was used at the
physicians’ discretion. The primary endpoint was FN incidence during all cycles. Multivariate logistic
regression analysis was performed to identify T-FN risk factors.
Results: Of 1005 enrolled patients, 980 women treated with FEC, E(A)C, and TC were analyzed. The FN
incidence proportions in all patients were 22.5%, 27.5%, and 33.9% for FEC, E(A)C, and TC, respectively.
Those of T-FN were 27.7%, 22.4%, and 36.6%; those of S-FN were 17.3%, 32.4%, and 31.5% with more
frequent primary PEG-G usage. The relative dose intensity (RDI) of the 3 regimens was 0.85 in both
groups. In the analysis of risk factors, TC (odds ratio ¼ 2.67), age  65 years (2.24), and pretreatment
absolute neutrophil count (ANC)/1000 ml (0.8) remained significant.ery and Oncology, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan.
a).
r Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/
T. Ishikawa, K. Sakamaki, K. Narui et al. The Breast 56 (2021) 70e77Conclusions: FN incidences were above 20% in the 3 regimens, with TC showing the highest. RDI was
maintained at a high level in both visiting and non-visiting groups. Patient-related risk factors were age
and pretreatment ANC.
© 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Febrile neutropenia (FN) is a major hematologic side effect
associated with chemotherapy, and results in dose reduction and
delayed treatment [1]. Both conditions are directly linked to a
reduction in relative dose intensity (RDI), which impedes cure of
patients with early breast cancer [2,3]. In addition, FN is a poten-
tially life-threatening toxicity similarly to sepsis, and may require
emergency admission and hospitalization [4,5]. For patients with a
high risk of FN, primary pegfilgrastim (PEG-G) prophylaxis is rec-
ommended in clinical practice guidelines [6e8]. A meta-analysis
showed that primary PEG-G support improved the overall sur-
vival of breast cancer patients with FN undergoing intensified
chemotherapy [9]. However, primary PEG-G is associated with a
higher risk for secondary malignancies in solid tumor or malignant
lymphoma treatment [9]. The toxicities and also costs associated
with PEG-G deserve a careful and systematic study. Therefore,
identifying the risk factors and predictors of FN is clinically
important to determine the appropriate indication of primary PEG-
G.
The incidence of FN is associated with the myelosuppressive
effect of chemotherapy regimens and individual patient risk fac-
tors. Regimens are categorized into 3 groups according to the risk of
FN. Primary PEG-G is recommended for patients when using high-
risk regimens with an FN incidence of >20%, whereas primary PEG-
G is required for patients with risk factors for moderate-risk regi-
mens with an FN incidence of 10%e20% [6e8].
As for patient-related risk factors of FN, advanced age (>65
years) is listed in all guidelines [6e8]. Except for age, slightly
different factors appear in various guidelines. Advanced disease,
previous chemotherapy or radiation therapy, pre-existing neu-
tropenia, bone marrow involvement with the tumor, infection,
open wounds, poor performance or nutritional status, poor renal
function, liver dysfunction, and multiple comorbid conditions are
listed as risk factors of FN [6e8].
Ethnic origin may be related to the incidence of FN, with Asians
reported to be more vulnerable to FN than Caucasians [10e13]. In a
study comparing hematologic toxicity during neoadjuvant and
adjuvant FEC treatments in breast cancer patients of 4 races, Asians
had a significantly higher rate of grade 3 hematologic toxicity than
Caucasians, African-Americans, and Hispanics [12]. This ethnic
difference is partly due to differences in physical constitutions, such
as the activity of metabolic enzymes [12]. Another possible reason
is that calculation of the therapeutic dose practically tends to be
based on the ideal weight and not on the actual weight in obese
patients, who are less common in Asians [14]. However, only a few
studies have examined the incidences and risk factors of FN in
Asian patients with breast cancer [12,13]. Examination of these
incidences and risk factors may help clarify the indication of pri-
mary PEG-G based on race.
For the prevention or early treatment of FN, prophylactic or
therapeutic oral antibiotic administration is an alternative to pri-
mary PEG-G prophylaxis. In daily clinical practice, some physicians
prescribe antibiotics and instruct patients to take these drugs if
they have a fever, instead of using primary PEG-G or performing71blood tests at the time the nadir is expected. With the current
empirical prescription of oral antibiotics, it is practically important
to know whether this method is safe in the short and long terms,
and in terms of excessive use of antibiotics for prophylaxis.
These backgrounds indicate the importance of evaluating FN in
breast cancer patients in Asian countries. The purpose of this cohort
study is to evaluate the incidences and risk factors of FN in Japanese
breast cancer patients who received 3 mainstream adjuvant regi-
mens according to 2 treatment policies for FN.2. Patients and methods
2.1. Study design
A multicenter, prospective observational study was performed
in female patients who were diagnosed with clinical stages I to III
breast ductal or lobular carcinoma andwere scheduled for adjuvant
or neoadjuvant chemotherapy using the following 6 regimens [15]:
(1) 4 cycles of 5-fluorouracil 500 mg/m2 þ epirubicin 100 mg/
m2þ cyclophosphamide 500mg/m2 (FEC), (2) 4 cycles of epirubicin
90 mg/m2 (doxorubicin 60 mg/m2) þ cyclophosphamide 600 mg/
m2 (E(A)C), (3) 4 cycles of docetaxel 60e100 mg/m2 (DOC), (4) 6
cycles of docetaxel 75 mg/m2 þ doxorubicin 50 mg/
m2 þ cyclophosphamide 500mg/m2 (TAC), (5) 4 cycles of docetaxel
75 mg/m2 þ cyclophosphamide 600 mg/m2 (TC), and (6) 6 cycles of
docetaxel 75 mg/m2 þ carboplatin AUC6 þ trastuzumab 8 mg/kg
(TCbH). There was no provision regarding the administration of
PEG-G, and it was used at the discretion of physicians. Early
monitoring after the study initiation showed that only few patients
received the TAC, TCbH, and DOC regimens, and identifying the
incidence of FN for these regimenswould be difficult. Therefore, the
protocol was revised in July 2016 to limit the regimens that would
be evaluated to FEC, E(A)C, and TC.
Patients were consecutively enrolled from August 2015 to July
2017 from 44 institutions. The number of patients varied from 1 to
98 in various institutions. Written informed consent was obtained
from all patients. The study was approved by the protocol review
committee of the Comprehensive Support Project for Oncological
Research of Breast Cancer on February 10, 2015 and by the insti-
tutional review board of TokyoMedical University on April 28, 2015
(No. 3044). This trial was registered at the UMIN Clinical Trials
Registry as UMIN 000017857.2.2. Baseline assessment
After enrollment, the following information was collected as
baseline data: date of birth; site of breast cancer (left or right);
pathological stage; status of lymph node metastasis; expression
status of estrogen receptor (ER), progesterone receptor (PgR) and
human epidermal growth factor receptor type 2 (HER2); nuclear
grade; histological grade; performance status (PS); previous treat-
ment for breast cancer (endocrine, radiation and surgical treat-
ments); comorbidity (renal disorder, liver disorder, neutropenia
before treatment); and height and weight.
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The following items were investigated on day 1 of each treat-
ment cycle: PS; type and dose of chemotherapeutic agent; and date
of administration. Body temperature, laboratory values (white
blood cell count, neutrophil count), and adverse event (AE)s were
investigated at regular visits (or on admission) for chemotherapy
and at unscheduled visits for fever and AEs. Information on the
administration of primary PEG-G or therapeutic granulocyte
colony-stimulating factor (G-CSF) and antibiotics was investigated
in each treatment cycle.
2.4. Patient diary
During the chemotherapy period, patients measured their body
temperature in the morning and evening, and when they felt a
fever, and recorded the data in a diary.
2.5. Evaluation and definition of FN
Preliminary survey prior to this study revealed that each insti-
tution had different policies for responding to a fever in patients
undergoing chemotherapy. These policies were broadly divided
into 2 types. Some facilities instructed patients to visit the hospital
if they developed a fever and to undergo a blood test for FN diag-
nosis. Other facilities asked patients to immediately take a pre-
specified antibiotic if they developed a fever during chemo-
therapy without visiting the hospital, and only to visit if their fever
persisted.
The present study used an observational design based on daily
clinical practice. Thus, if patients developed an axillary temperature
37.5 C, 2 procedures were used to manage the fever: (1) undergo
a hematologic test with a hospital visit (visiting group) or (2) take a
prescribed oral antibiotic without a hospital visit (non-visiting
group).
We defined FN in 2 ways in accordance with the above-
mentioned procedures (visiting and non-visiting groups) for
managing fever during chemotherapy, namely, True-FN (T-FN) and
Surrogate-FN (S-FN). T-FN was defined as an axillary temperature
37.5 C and an absolute neutrophil count (ANC) of <500/ml
(visiting group). S-FN was defined as an axillary temperature
37.5 C and oral antibiotic/antipyretic intake according to the
instructions of each hospital (non-visiting group). Each facility was
required to clarify which policy was used to manage FN at the time
of the study.
2.6. Endpoints
The primary endpoint was the incidence of FN for the whole 4
cycles of treatment. The patient was used as an analysis unit. The
secondary endpoints were (1) FN incidence in the 1st cycle, (2)
grade 4 neutropenia, (3) hospitalization, (4) use of therapeutic G-
CSF, (5) use of therapeutic antibiotics, (6) AEs due to FN, (7) RDI, and
(8) serious AEs.
2.7. Statistical analysis
In the analysis of the primary endpoint, the incidence pro-
portions of FN for each regimen were estimated. To evaluate the
difference between the 2 treatment policies, we calculated 3 types
of proportions: (1) number of T-FN and S-FN cases/total number of
patients in the entire population, (2) number of T-FN cases/number
of patients in the visiting group, and (3) number of S-FN cases/
number of patients in the non-visiting group.
In the analyses of the secondary endpoints, the endpoints were72summarized by proportions and were compared between the
visiting and non-visiting groups in each regimen. RDI was calcu-
lated as the number and proportion of patients in which 85% or
more of the standard dose could be administered. The data show
the proportion of cases with an RDI of 85% or higher for each cycle
and for all cycles. Grade 4 neutropenia was summarized only in the
visiting group.
To evaluate the risk factors of FN, we predefined regimens, age,
PS, stage, history of chemotherapy or radiotherapy, infectious
wounds, open wounds, ANC, and renal and liver dysfunctions as
possible risk factors using the following categorization: age: < 65
vs  65 years; PS: 0 vs  1; stage: I or II vs III; prior chemotherapy:
positive vs negative; radiotherapy: positive vs negative; infectious
wound: positive vs negative; open wound: positive vs negative;
ANC: < 1500 vs  1500/ml; renal dysfunction: Cr < 1.5 vs  1.5; and
liver dysfunction: AST/ALT or total bilirubin >3 or 1.5 times the
institutional normal range. Risk factors were evaluated in the
visiting group. Multiple logistic regression analysis was used to
assess the risk factors of T-FN, and the odds ratio (OR) and 95%
confidence interval (CI) were calculated using T-FN in the visiting
group as the outcome measure.
The target sample size was calculated based on interval esti-
mation, as described in detail previously [15]. From the clinical
perspective, the admissible 95% CIs were the estimated incidence
proportion ±5%. If the true incidence proportion is 10% or 20%, the
required number of cases was 165 or 264 to achieve an admissible
95% CI. In this sample size calculation, the incidence proportions in
all the enrolled patients were considered based on the speculation
that these incidence proportions were similar between the visiting
and non-visiting groups. Considering that the number of patients
who use TAC, TCbH, and DOC is not very large, we set the target
sample size to 1000 for the 6 regimens. Initially, 200 patients were
planned for the 3 major regimens of E(A)C, FEC, TC and DOC to
achieve 95% CI. For TAC and TCbH, 50 patients were planned for
these regimens in consideration of feasibility rather than 95% CI.
However, early monitoring after the study initiation showed that
only few patients received these regimens, and identifying the
incidence of FN for these regimens would be difficult. Thus, the
protocol was revised in July 2016 to limit the regimens to be
evaluated to FEC, E(A)C, and TC with 330 cases each.
3. Results
From August 2015 to July 2017, a total of 1005 patients with
stages I to III breast cancer were consecutively enrolled in the
present study. Of these 1005 patients, 489 patients were registered
in the visiting group. Among these 489 patients, 11 were excluded
because of chemotherapy interruption and 1 was excluded owing
to being lost to follow-up. The reasons for chemotherapy inter-
ruption in the 11 patients were refusal of study enrollment in 4
patients, refusal of chemotherapy in 2 patients, change of hospital
in 3 patients, change of treatment regimen in 1 patient, and
detection of metastatic disease in 1 patient. A total of 516 patients
were registered in the non-visiting group. Among these 516 pa-
tients, 3 were excluded because of consent withdrawal and 10 were
excluded owing to being lost to follow-up. Finally, 980 patients,
namely, 477 (48.7%) in the visiting group and 503 (51.3%) in the
non-visiting group, were analyzed in the present study (Fig. 1).
The patient demographics and background factors of the regi-
mens are shown in Table 1. The chemotherapy regimens adminis-
tered in the visiting and non-visiting groups were FEC in 170 (36%)
and 168 (33%), E(A)C in 165 (35%) and 170 (34%), and TC in 142
(30%) and 165 (33%), respectively. The TC regimenwas mainly used
for patients with earlier stages and ER-positive disease at the
adjuvant treatment setting in contrast to the FEC and E(A)C
Fig. 1. Flow diagram of patient enrollment and selection. In this study, 1005 patients with stages I to III breast cancer were consecutively enrolled from August 2015 to July 2017. Of
these 1005 patients, 489 patients were registered in the visiting group. Among these 489 patients, 11 were excluded because of chemotherapy interruption and 1 was excluded
owing to being lost to follow-up. A total of 516 patients were registered in the non-visiting group. Among these 516 patients, 3 were excluded because of consent withdrawal and 10
were excluded owing to being lost to follow-up. Finally, 980 patients, namely, 477 (48.7%) in the visiting group and 503 (51.3%) in the non-visiting group, were analyzed in the
present study.
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at the neoadjuvant treatment setting. The proportion of primary
PEG-G was higher in the patients receiving the TC regimen than in
the patients receiving the FEC or E(A)C regimen, and in the non-
visiting group than in the visiting group (Table 1, Fig. 2, and
Supplementary Table 1). Very few patients had a history of radia-
tion therapy, current wound infections, open wounds, renal
dysfunction, and hepatic dysfunction, which were possible risk
factors of FN.3.1. Incidence of febrile neutropenia
The estimated incidence proportions and 95% CIs of FN during 4
cycles of treatment were 22.5% (18.1%e27.3%) for FEC, 27.5%
(22.8%e32.6%) for E(A)C, and 33.9% (28.6%e39.5%) for TC in the
entire study population; 27.7% (21.1%e35.0%) for FEC, 22.4%
(16.3%e29.6%) for E(A)C, and 36.6% (28.7%e45.1%) for TC in the
visiting group; and 17.3% (11.8%e23.8%) for FEC, 32.4% (25.4%e
39.9%) for E(A)C, and 31.5% (24.5%e39.2%) for TC in the non-visiting
group (Table 2). These results did not consider whether PEG-G was
administered.
The incidence proportion of T-FN was approximately 10% higher
than that of S-FN with the FEC regimen, whereas that of S-FN was
approximately 10% higher with the E(A)C regimen, with no
consistent trend. The proportions of FN incidence and PEG-G dur-
ing each treatment cycle are shown in Fig. 2 and Supplementary
Table 1. The Incidence proportion of FN in the 1st cycle was the
highest at approximately 20%, and decreased to 3%e8% after the
second cycle. The proportion of primary PEG-G in the 1st cycle was
higher in the non-visiting group at 20%e30%, with the highest at
52% for the TC regimen. The PEG-G rate was gradually increased
after the 2nd cycle in the visiting group.3.2. Secondary endpoints
The results of the analysis of the secondary endpoints are
summarized in Table 3. Hospitalization occurred most often in the
E(A)C regimen in the visiting group at 10.6%. Grade 3 or 4 AEs were73foundmore frequently in the visiting group than in the non-visiting
group (30.1% vs 16.5% in FEC, 42.0% vs 29.2% in TC). Therapeutic
antibiotics were used for these regimens more often in the visiting
group (46.1% vs 37.6% in FEC, 56.9% vs 46.2% in TC). In addition, the
rate of therapeutic G-CSF usage was higher in the visiting group in
all the 3 regimens. FN-related severe AEs were rarely found at only
0.2% for stomatitis and 0.1% for sore throat. In all the 3 regimens, the
percentage of cases with an RDI 0.85 was high at approximately
90% in both groups.3.3. Risk factors
Risk factors were evaluated in the visiting group. In the logistic
regression analysis, we reconsidered which possible risk factors
were used because few patients had a low PS, prior chemotherapy,
radiation therapy, infected wounds, open wounds, renal dysfunc-
tion, and hepatic dysfunction. We used regimen (FEC vs E(A)C vs
TC), age (<65 vs  65), ANC, stage (I vs II vs III), treatment setting
(adjuvant vs neoadjuvant), primary PEG-G administration (yes vs
no) in the logistic regression models for exploratory evaluation of
risk factors. As the ANC of most patients was >1500/ml, ANC was
used as a continuous variable. Risk factors were evaluated in the
visiting group, with T-FN used for event data.
Logistic regression analysis revealed that the TC regimen
(OR ¼ 2.62, 95% CI: 1.34e5.12), age  65 (OR ¼ 2.24, 95% CI:
1.34e3.75), and ANC/1000 ml (OR ¼ 0.8, 95% CI: 0.67e0.95) were
significant risk factors of FN. Adjuvant treatment setting (OR¼ 0.51,
95% CI: 0.29e0.88) and primary PEG-G administration (OR ¼ 0.04,
95% CI: 0.01e0.34) were significant protective factors against FN
(Table 4).
To search for risk factors as a decision tool for PEG-G usage,
another multivariate analysis was conducted in the patients
without PEG-G at the 1st cycle (Supplementary Table 3). The results
were not significantly different from those shown in Table 4.4. Discussion
This study set out to evaluate the incidences and risk factors of
Table 1























50.5 (22e78) 50 (25e78) 52 (22e74) 54 (27e77) 55 (27e76) 53 (30e77) 53 (30e80) 52 (30e80) 53 (31e76)
<65 292 (86.4%) 150 (88.2%) 142 (84.5%) 251 (74.9%) 120 (72.7%) 131 (77.1%) 236 (76.9%) 111 (78.2%) 125 (75.8%)
65 46 (13.6%) 20 (11.8%) 26 (15.5%) 84 (25.1%) 45 (27.3%) 39 (22.9%) 71 (23.1%) 31 (21.8%) 40 (24.2%)
ECOG PS
0 337 (99.7%) 169 (99.4%) 168 (100%) 334 (99.7%) 164 (99.4%) 170 (100%) 305 (99.3%) 142 (100%) 163 (98.8%)
1 1 (0.3%) 1 (0.6%) 0 (0%) 1 (0.3%) 1 (0.6%) 0 (0%) 2 (0.7%) 0 (0%) 2 (1.2%)
Stage
I 35 (10.4%) 10 (5.9%) 25 (14.9%) 82 (24.5%) 47 (28.5%) 35 (20.6%) 115 (37.5%) 46 (32.4%) 69 (41.8%)
IIA 99 (29.3%) 51 (30%) 48 (28.6%) 97 (29.0%) 48 (29.1%) 49 (28.8%) 116 (37.8%) 57 (40.1%) 59 (35.8%)
IIB 106 (31.4%) 55 (32.4%) 51 (30.4%) 80 (23.8%) 36 (21.8%) 44 (25.9%) 64 (20.8%) 32 (22.5%) 32 (19.4%)
IIIA 41 (12.1%) 24 (14.1%) 17 (10.1%) 39 (11.6%) 19 (11.5%) 20 (11.8%) 7 (2.3%) 4 (2.8%) 3 (1.8%)
IIIB 21 (6.2%) 7 (4.1%) 14 (8.3%) 15 (4.5%) 10 (6.1%) 5 (2.9%) 5 (1.6%) 3 (2.1%) 2 (1.2%)
IIIC 36 (10.6%) 23 (13.5%) 13 (7.7%) 22 (6.6%) 5 (3.0%) 17 (10.0%) 0 (0%) 0 (0%) 0 (0%)
Status of estrogen receptor
Positive 204 (60.4%) 112 (65.9%) 92 (54.8%) 207 (61.8%) 102 (61.8%) 105 (61.8%) 251 (81.8%) 123 (86.6%) 128 (77.6%)
Negative 134 (39.6%) 58 (34.1%) 76 (45.2%) 128 (38.2%) 63 (38.2%) 65 (38.2%) 56 (18.2%) 19 (13.4%) 37 (22.4%)
Status of HER2
0、1þ 166 (49.1%) 84 (49.4%) 82 (48.8%) 162 (48.4%) 66 (40.0%) 96 (56.5%) 199 (64.8%) 104 (73.2%) 95 (57.6%)
2þ/FISH() 42 (12.4%) 20 (11.8%) 22 (13.1%) 44 (13.1%) 28 (17.0%) 16 (9.4%) 48 (15.6%) 20 (14.1%) 28 (17.0%)
3þ/FISH() 129 (38.2%) 66 (38.8%) 63 (37.5%) 128 (38.2%) 71 (43.0%) 57 (33.5%) 60 (19.5%) 18 (12.7%) 42 (25.4%)
Unknown 1 (0.3%) 0 (0%) 1 (0.6%) 1 (0.3%) 0 (0%) 1 (0.6%) 0 (0%) 0 (0%) 0 (0%)
Treatment setting
Neoadjuvant 237 (70.1%) 122 (71.8%) 115 (68.5%) 145 (43.3%) 83 (50.3%) 62 (46.5%) 24 (7.8%) 6 (4.2%) 18 (10.9%)
Adjuvant 101 (29.9%) 48 (28.2%) 53 (31.5%) 190 (56.7%) 82 (49.7%) 108 (63.5%) 283 (92.2%) 136 (95.8%) 147 (89.1%)
Use of PEG-G for 1st cycle
Yes 73 (21.6%) 8 (4.7%) 65 (38.7%) 23 (6.9%) 3 (1.8%) 20 (11.8%) 106 (34.5%) 20 (14.1%) 86 (52.1%)






















FEC, fluorouracil þ epirubicin þ cyclophosphamide.
E(A)C, epirubicin (doxorubicin) þ cyclophosphamide.
TC, docetaxel þ cyclophosphamide.
FISH, Fluorescence in situ hybridization.
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according to 2 treatment policies for FN. To our knowledge, this is
the first prospective study directly comparing FN incidences be-
tween 3 mainstream regimens. The FN proportions of these 3
regimens were above 20%. The FN proportion of TC could be higher
than 40% because the T-FN proportion of TC was 36.6% when pri-
mary PEG-G was used at the 1st cycle in 14.1% of the patients
(Table 2, Supplementary Table 1). The T-FN proportions of FEC and
E(A)C were 27.7% and 22.4% when primary PEG-G was respectively
used at the 1st cycle in 4.7% and 1.8% of the patients, which are very74low patient rates particularly for the latter (Table 2, Supplementary
Table 1). Although the patient characteristics were different in the 3
regimens (Table 1), it is clear that TC is the regimen that most
frequently induces the development of FN. In all the regimens, the
FN proportions decreased at the 2nd cycle with the increasing us-
age of PEG-G (Fig. 2) or antibiotics (data not shown) in the second
and subsequent cycles, which is defined as secondary prophylaxis
in response to the low neutrophil counts or FN-related events
observed in the first cycle. In previous reports in which FN without
primary PEG-G at the 1st cycle was investigated in Caucasian
Fig. 2. Proportions of FN incidence and primary PEG-G during each treatment cycle. In all the regimens, the FN proportions (solid lines) were the highest in the 1st cycle and
decreased after the second cycle in response to the increasing usage of primary PEG-G (dotted lines). The proportions of primary PEG-G (dotted lines) were higher in the non-
visiting group (triangles) than in the visiting group (circles) in the FEC and TC regimens, with the highest at more than 50% in the non-visiting group for the TC regimen.
Table 2
Incidence proportions of FN during all courses of chemotherapy.
All patients T-FN(Visiting Group) S-FN(Non-Visiting Group)
N Proportion (95%Cl) N Proportion (95%Cl) N Proportion (95%Cl)
FEC 338 22.5% (18.1%e27.3%) 170 27.7% (21.1%e35.0%) 168 17.3% (11.8%e23.8%)
E(A)C 335 27.5% (22.8%e32.6%) 165 22.4% (16.3%e29.6%) 170 32.4% (25.4%e39.9%)
TC 307 33.9% (28.6%e39.5%) 142 36.6% (28.7%e45.1%) 165 31.5% (24.5%e39.2%)
F
FEC, fluorouracil þ epirubicin þ cyclophosphamide.
E(A)C, epirubicin (doxorubicin) þ cyclophosphamide.
TC, docetaxel þ cyclophosphamide.
Table 3
Results of analysis of secondary endpoints.
FEC E(A)C TC
All patients Visiting Non-visiting All patients Visiting Non-visiting All patients Visiting Non-visiting
FN incidence in the first course 62 (18.3%) 42 (24.7%) 20 (11.9%) 64 (19.1%) 27 (16.4%) 37 (21.8%) 66 (21.5%) 36 (25.4%) 30 (18.2%)
Grade 4 neutropenia ー 46 (27.1%) ー ー 42 (25.5%) ー ー 30 (21.1%) ー
Hospitalization 21 (6.5%) 12 (7.3%) 9 (5.7%) 24 (7.4%) 17 (10.6%) 7 (4.2%) 22 (7.7%) 11 (8.2%) 11 (7.2%)
Use of therapeutic G-CSF (all cycles) 52 (16.2%) 43 (26.2%) 9 (5.7%) 55 (16.9%) 42 (26.3%) 13 (7.8%) 62 (21.5%) 49 (35.3%) 13 (8.7%)
Use of therapeutic antibiotics (all cycles) 135 (41.9%) 76 (46.1%) 59 (37.6%) 143 (44.0%) 60 (37.7%) 83 (50.0%) 150 (51.2%) 78 (56.9%) 72 (46.2%)
Grade 3 or 4 adverse events 76 (23.5%) 50 (30.1%) 26 (16.5%) 82 (24.9%) 39 (24.4%) 43 (25.4%) 103 (35.3%) 58 (42.0%) 45 (29.2%)
FN-related adverse events (grade 3 or above, all cycles)
Stomatitis 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 2 (0.65%) 2 (1.41%) 0 (0%)
sore throat 0 (0%) 0 (0%) 0 (0%) 1 (0.3%) 1 (0.61%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Relative dose intensitya 307 (90.8%) 155 (91.2%) 152 (90.5%) 311 (92.8%) 150 (90.9%) 161 (94.7%) 272 (88.9%) 129 (90.9%) 143 (87.2%)
RDI (0.85)
1st cycle 337 (99.7%) 170 (100%) 167 (99.4%) 332 (99.1%) 162 (98.2%) 170 (100%) 305 (99.7%) 142 (100%) 163 (99.4%)
2nd cycle 326 (98.2%) 165 (98.8%) 161 (97.6%) 321 (97.0%) 154 (94.5%) 167 (99.4%) 291 (98.3%) 134 (97.1%) 157 (99.4%)
3rd cycle 317 (97.5%) 159 (98.2%) 158 (96.9%) 312 (95.1%) 150 (93.2%) 162 (97.0%) 281 (96.9%) 130 (96.3%) 151 (97.4%)
4th cycle 309 (96.9%) 157 (97.5%) 152 (96.2%) 305 (93.9%) 145 (90.6%) 160 (97.0%) 273 (97.2%) 129 (96.3%) 144 (98.0%)
FEC, fluorouracil þ epirubicin þ cyclophosphamide E(A)C, epirubicin (doxorubicin) þ cyclophosphamide TC, docetaxel þ cyclophosphamide.
G-CSF, granulocyte colony-stimulating factor RDI, relative dose intensity.
a For all 4 courses  0.85.
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[16e21]. The comparison of these with 22.4% in E(A)C of this study
revealed that an ethnic difference may exist and that the Japanese
population may be vulnerable to FN.
In the analysis of secondary endpoints, FN-related events were75generally well managed with a few severe events, low rates of
hospitalization, and no fatal cases. It is not reasonable to compare
these FN-related events between the non-visiting and visiting
groups because of many differences in their baseline characteris-
tics. However, grade 3 or 4 AEs and hospitalization more frequently
Table 4
Multivariate analysis for exploring the risk factors of FN.
Parameter Odds ratio 95% CI p -value
Regimen TC 2.67 1.36e5.26 0.005
E(A)C 0.66 0.38e1.14 0.137
FEC ref
Age >65 2.24 1.34e3.75 0.002
Neutrophils (continuous) /1000 mL 0.8 0.67e0.95 0.012
Stage III 0.98 0.48e1.99 0.961
II 0.82 0.47e1.44 0.492
I ref
Treatment setting Adjuvant 0.51 0.29e0.88 0.017
Neoadjuvant ref
Primary PEG-G Yes 0.04 0.01e0.34 0.003
No ref
FEC, fluorouracil þ epirubicin þ cyclophosphamide.
E(A)C, epirubicin (doxorubicin) þ cyclophosphamide.
TC, docetaxel þ cyclophosphamide.
PEG-G, pegfilgrastim.
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Possibly related to these increased events, therapeutic G-CSF and
antibiotics were used more frequently in the visiting group
(Table 3). These trends were preserved in limited cases with pri-
mary PEG-G not used at the 1st cycle (data not shown). Importantly,
the RDIs in all the 3 regimens were maintained at sufficiently high
levels in both groups (Table 3).
As for FN risk factors, we analyzed the entire cohort with PEG-G
as one of the confounding factors. As for patient-related FN risk
factors, advanced age and low pretreatment ANC remained signif-
icant in the multivariate analysis (Table 4). We also performed
anothermultivariate analysis in the patients without PEG-G used at
the 1st cycle (Supplementary Table 3). It is possible that the base-
line characteristics were different between the patients with and
without PEG-G at the 1st cycle. However, the results of the other
multivariate analysis were not significantly different from the re-
sults of the multivariate analysis shown in Table 4.
Notably, age has been identified as a risk factor of FN in any
guidelines [6e8]. The age of 65 years has been used as a threshold
established from analyses including hematologic malignancies in
Caucasian countries [22,23]. By comparing the FN proportion of
E(A)C in Caucasians with that in Asians in this study, it clearly
suggests that an ethnic difference in the vulnerability to FN may
exist. Thus, it is necessary to determine the threshold of the age for
FN in Japanese patients.
The guidelines of The American Society of Clinical Oncology and
National Comprehensive Cancer Network have listed pre-existing
neutropenia as a risk factor of FN. However, the threshold has not
been fixed for prophylaxis. The present prospective study revealed
a significant association of pretreatment ANCwith FN (Table 4). The
categorical analysis on ANC showed a consistent increase in the
odds ratio on FN (Supplementary Table 2). Thus, the pretreatment
ANC could be a reliable marker for FN development. Previously,
there were retrospective studies identifying ANC as a predictive
factor of FN [24,25]. These studies investigated 741 patients
administered with FEC retrospectively [24] and validated their
findings with another set of 263 patients administered with TAC
[25]. The combination of ANC and absolute lymphocyte count was
reported to be valuable in predicting neutropenic events including
FN, in which the association between ANC and FN appears to be
most significant [24]. However, the threshold of ANC was not
investigated in these studies. Thus, plans are underway for a further
study to establish the ANC threshold for predicting FN.
There are several limitations in this study. First, in the visiting
group, 47 of the 477 cases (9.8%) did not visit hospitals for a blood
test and 12 cases (2.5%) did a blood test 3 days after having a fever.76No regulation was established for antibiotic usage. These might
have underestimated the FN frequency in the visiting group. Sec-
ond, the neoadjuvant setting remained as one of the risk factors of
FN. It may be unreasonable to make a comparison between neo-
adjuvant chemotherapy and adjuvant chemotherapy because these
settings were diametrically related with the patient characteristics
and regimens. The relationship of the neoadjuvant setting with FN
may be biased owing to multicollinearity in the multivariate anal-
ysis. Third, the managements of FN in the visiting and non-visiting
groups were dependent on the institutions, which may result in
different characteristics between these 2 groups.
5. Conclusion
The FN proportions in the FEC, E(A)C, and TC regimens were
above 20%, with the TC regimen showing the highest proportion.
However, regarding the present status, the RDI was maintained at a
high level and FN-related events were all well managed in both the
visiting and non-visiting groups. Thus, it remains clinically mean-
ingful to select patients with a high risk of FNwith the adequate use
of primary PEG-G. Age and pretreatment ANC were found to be
patient-related risk factors of FN development. The thresholds of
these 2 factors, which might be different from the current guide-
lines, warrant further investigation.
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